Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine
© 2022 The Authors..
Matching the treatment to an individual patient's tumor state can increase therapeutic efficacy and reduce tumor recurrence. Circulating tumor cells (CTCs) derived from solid tumors are promising subjects for theragnostic analysis. To analyze how CTCs represent tumor states, we established cell lines from CTCs, primary and metastatic tumors from a mouse model and provided phenotypic and multiomic analyses of these cells. CTCs and metastatic cells, but not primary tumor cells, shared stochastic mutations and similar hypomethylation levels at transcription start sites. CTCs and metastatic tumor cells shared a hybrid epithelial/mesenchymal transcriptome state with reduced adhesive and enhanced mobilization characteristics. We tested anti-cancer drugs on tumor cells from a metastatic breast cancer patient. CTC responses mirrored the impact of drugs on metastatic rather than primary tumors. Our multiomic and clinical anti-cancer drug response results reveal that CTCs resemble metastatic tumors and establish CTCs as an ex vivo tool for personalized medicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
iScience - 25(2022), 10 vom: 21. Okt., Seite 105081 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jia-Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 27.12.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2022.105081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347196268 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347196268 | ||
| 003 | DE-627 | ||
| 005 | 20231226033251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2022.105081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347196268 | ||
| 035 | |a (NLM)36204272 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Jia-Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a Matching the treatment to an individual patient's tumor state can increase therapeutic efficacy and reduce tumor recurrence. Circulating tumor cells (CTCs) derived from solid tumors are promising subjects for theragnostic analysis. To analyze how CTCs represent tumor states, we established cell lines from CTCs, primary and metastatic tumors from a mouse model and provided phenotypic and multiomic analyses of these cells. CTCs and metastatic cells, but not primary tumor cells, shared stochastic mutations and similar hypomethylation levels at transcription start sites. CTCs and metastatic tumor cells shared a hybrid epithelial/mesenchymal transcriptome state with reduced adhesive and enhanced mobilization characteristics. We tested anti-cancer drugs on tumor cells from a metastatic breast cancer patient. CTC responses mirrored the impact of drugs on metastatic rather than primary tumors. Our multiomic and clinical anti-cancer drug response results reveal that CTCs resemble metastatic tumors and establish CTCs as an ex vivo tool for personalized medicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Omics | |
| 650 | 4 | |a Precision medicine | |
| 650 | 4 | |a Transcriptomics | |
| 700 | 1 | |a Chou, Hsu-Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Syer Choon |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yen-Jang |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Kuan-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Chin-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Tung, Chien-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Chung-Tsai |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jocelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Hsiao-Fen |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, Po-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Chun-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Dunn, Alexander R |e verfasserin |4 aut | |
| 700 | 1 | |a Frank, Curtis W |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yi-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Muh-Hwa |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Ying-Chih |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 25(2022), 10 vom: 21. Okt., Seite 105081 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:10 |g day:21 |g month:10 |g pages:105081 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2022.105081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 10 |b 21 |c 10 |h 105081 | ||